iOmx Therapeutics AG

Developing next-generation targeted cancer immunotherapy treatments

Add To Watchlist
General Information
Company Name
iOmx Therapeutics AG
Founded Year
2016
Location (Offices)
Germany +1
Founders / Decision Makers
Marcus Irsfeld - Chief Financial Officer Nisit Khandelwal - Co-Founder and Managing Director Murray Yule - CMO Philipp Beckhove - Co-Founder Christine Rothe - Chief Development Officer Nils Debus - Chief Business Officer (CBO) Apollon Papadimitriou - Chief Executive Officer
Number of Employees
60
Industries
Biopharma, Health Care, Pharmaceutical
Funding Stage
Series B
Social Media

iOmx Therapeutics AG - Company Profile

iOmx Therapeutics AG is a young, dynamic startup based in Martinsried/Munich, Germany, focused on developing next-generation targeted cancer immunotherapy treatments. The company, founded in 2016, is backed by a powerful technology platform and internationally renowned investors. iOmx is actively advancing a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development in the Biopharma, Health Care, and Pharmaceutical industries. Notably, the company recently secured a €65.00M Series B investment on 05 October 2021 from prominent investors including Sofinnova Partners, Wellington Partners, MERL Ventures Fund, and MIG AG. Imprint: iomx.com/imprint.

Taxonomy: Immuno-oncology, Cancer therapeutics, Immune checkpoint modulators, Tumor resistance mechanisms, Drug development, Cancer immunotherapy, Targeted treatments, Clinical development, Tumor cell analysis, Immune resistance, Pre-clinical research, Therapeutic immunology, Cell surface molecules, Novel immune targets

Funding Rounds & Investors of iOmx Therapeutics AG (2)

View All
Funding Stage Amount No. Investors Investors Date
Series B €65.00M 4
Sofinnova Partners, investor in iOmx Therapeutics AG's Series B round Wellington Partners, investor in iOmx Therapeutics AG's Series B round MERL Ventures Fund, investor in iOmx Therapeutics AG's Series B round MIG AG, investor in iOmx Therapeutics AG's Series B round
05 Oct 2021
Series A €40.00M 4
MPM Capital, investor in iOmx Therapeutics AG's Series A round Sofinnova Partners, investor in iOmx Therapeutics AG's Series A round Wellington Partners, investor in iOmx Therapeutics AG's Series A round MERL Ventures Fund, investor in iOmx Therapeutics AG's Series A round
20 Sep 2016

Latest News of iOmx Therapeutics AG

View All

No recent news or press coverage available for iOmx Therapeutics AG.

Similar Companies to iOmx Therapeutics AG

View All
IOmx - Similar company to iOmx Therapeutics AG
IOmx iOmx Therapeutics develops cancer treatments targeting immune checkpoint modulators on tumor cells. Targets identified through systematic screening.
AnaptysBio - Similar company to iOmx Therapeutics AG
AnaptysBio Transforming patient health by delivering innovative immunology therapeutics.
NextPoint Therapeutics, Inc. - Similar company to iOmx Therapeutics AG
NextPoint Therapeutics, Inc. Expanding the potential of immunotherapy
7 Hills Pharma - Similar company to iOmx Therapeutics AG
7 Hills Pharma First-in-concept platform of oral drugs to overcome immunotherapy resistance
Tridek-One - Similar company to iOmx Therapeutics AG
Tridek-One We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases
Circle Decoration Circle Decoration

Want to dive deeper into iOmx Therapeutics AG? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now